Prokaryotics, Inc.
Union, NJ · Biotech · Private
Medinamycin (MedM), a novel small-molecule antibiotic targeting bacterial peptidoglycan transglycosylation for treatment of antimicrobial-resistant Neisseria gonorrhoeae
prokaryotics.com →- Grants
- $14M
- 18 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae | $1,795,400 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | $295,541 | |
| Federal grant | Department of Health and Human Services · Phase II · Restoring Beta-lactam efficacy against methicillin-resistant Staphylococci | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae | $842,442 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci | $999,396 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci | $991,117 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis | $299,326 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci | $974,575 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis | $295,592 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics | $996,450 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an active site inhibitor of Fks1 as a broad spectrum antifungal agent | $299,697 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics | $977,454 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1702 | TEGA THERAPEUTICS INC | — | — |
| 1703 | BIOSPUTNIK LLC | — | — |
| 1704 | ONEVAX, LLC | — | — |
| 1705 | Prokaryotics, Inc. | — | — |
| 1706 | Phoenix Nest Inc. | — | — |
| 1707 | Remedy Labs, Inc. | — | $500K |
| 1708 | STOECKER MD, WILLIAM V | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.